Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Sacubitril/valsartan in heart failure: a guide for primary care

Sponsored by: This special issue and supplement were initiated and funded by Novartis. Novartis reviewed the publications for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Publication date: Friday, 21 October 2016

FRONT COVER Novartis Special issue This issue introduces a first-in-class oral treatment for heart failure – sacubitril/valsartan. It provides a comprehensive background to heart failure treatment in the UK, the pathophysiology of the disease and the pivotal trial data on the new drug. 

Articles give perspectives on the role of the GP, practice nurse, pharmacist and commissioner in using the drug, together with useful online heart failure resources for health professionals and patients.

Click on the link below for sacubitril/valsartan (Entresto▼™) clinical trial data, patient management guidelines and interviews with heart failure experts. The website aims to aid implementation of NICE and SMC guidance on managing heart failure with Entresto. https://www.action-hf.co.uk/

action-hf.co.uk is a promotional resource funded by Novartis Pharmaceuticals UK Ltd

Articles in this Special Edition:


HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a…

The UK faces an epidemic of heart failure (HF). NICE guidelines emphasise the importance of multidisciplinary assessment and care by HF specialists, evidence-based prescribing, and careful discharge planning after hospitalisation. This article highlights areas where improvements can be made in…

This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all…

The mechanisms underlying HF are complex and involve the interaction of many hormonal and molecular signalling pathways. These pathways form the basis of many pharmacological treatments, old and new. This article will examine the factors associated with the development of…

This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart…

The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the…

This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further…

A number of drug classes are used in the treatment of patients with heart failure. This illustrated Back to Basics poster describes the various drugs and their mechanisms of action to give health care professionals and their patients a greater…

Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need…

Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor.…

Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of…

Article search and filter